Sax Wealth Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 98.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,529 shares of the company’s stock after buying an additional 757 shares during the period. Sax Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,834,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. increased its stake in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after acquiring an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the subject of a number of research reports. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Barclays increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Beat-and-raise quarter reinforces growth outlook. Lilly reported second-quarter revenue of approximately $22.97 billion and EPS of $8.38, exceeding consensus estimates. Revenue increased 47.7% year over year, and management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, primarily because of strong demand for its diabetes and obesity medicines. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
- Positive Sentiment: Weight-loss portfolio continues to drive investor enthusiasm. Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion, widening Lilly’s lead over Novo Nordisk. Foundayo adoption is also gaining traction, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 regulatory filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
- Positive Sentiment: Analysts remain bullish. Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited durable incretin demand and the stronger long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth
- Positive Sentiment: Favorable legal news removes a potential overhang. Lilly and Novo Nordisk defeated an antitrust lawsuit concerning the GLP-1 drug market, reducing near-term litigation risk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
- Neutral Sentiment: Retatrutide is being offered to some patients before FDA approval. Early access could generate real-world experience and strengthen demand, but the treatment remains subject to regulatory approval and related safety scrutiny. Eli Lilly offers new weight loss drug to some patients before FDA approval
- Negative Sentiment: Profit-taking and valuation concerns may be limiting the response. Following the earnings-driven advance, Lilly trades at roughly 40 times earnings and near its record high. Investors may be demanding continued execution, while expanding access through Amazon and competing obesity drugs could increase pricing and market-share pressure.
Eli Lilly and Company Trading Up 0.1%
Shares of LLY opened at $1,186.71 on Monday. The company has a market capitalization of $1.12 trillion, a P/E ratio of 39.82, a P/E/G ratio of 1.38 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50-day moving average price of $1,159.38 and a 200 day moving average price of $1,047.62.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the business earned $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 23.22%.
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
